Idexx Laboratories (IDXX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 1,059,464 | 887,867 | 845,042 | 679,089 | 744,844 |
| Depreciation Amortization | 145,183 | 129,936 | 114,908 | 111,900 | 104,596 |
| Income taxes - deferred | 131,204 | -24,194 | -48,306 | -35,065 | -3,377 |
| Accounts receivable | -68,722 | -28,280 | -53,871 | -41,398 | -33,141 |
| Accounts payable and accrued liabilities | -8,573 | 8,086 | -557 | 3,467 | 11,233 |
| Other Working Capital | -227,514 | -133,238 | -72,429 | -273,530 | -137,523 |
| Other Operating Activity | 150,763 | 88,824 | 121,723 | 98,521 | 68,914 |
| Operating Cash Flow | $1,181,805 | $929,001 | $906,510 | $542,984 | $755,546 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 1,987 | 554 | 8,377 | -25,000 | N/A |
| PPE Investments | -124,676 | -120,922 | -133,631 | -148,838 | -119,549 |
| Net Acquisitions | N/A | -76,694 | N/A | -11,512 | -173,418 |
| Purchase Sale Intangibles | -13,550 | -10,000 | N/A | -10,000 | N/A |
| Other Investing Activity | -13,550 | -10,000 | 0 | -10,000 | 0 |
| Investing Cash Flow | $-136,239 | $-207,062 | $-125,254 | $-195,350 | $-292,967 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | N/A | N/A | 73,500 |
| Debt Issued | 250,000 | N/A | N/A | N/A | N/A |
| Debt Repayment | -428,385 | -75,000 | -75,000 | -75,000 | -50,000 |
| Common Stock Issued | 93,362 | 44,492 | 47,034 | 35,747 | 46,565 |
| Common Stock Repurchased | -1,224,203 | -847,565 | -81,895 | -830,317 | -762,339 |
| Other Financing Activity | 144,262 | 0 | -332,135 | 498,634 | -5,140 |
| Financing Cash Flow | $-1,164,964 | $-878,073 | $-441,996 | $-370,936 | $-697,414 |
| Exchange Rate Effect | 11,202 | -9,532 | 2,126 | -8,606 | -4,639 |
| Beginning Cash Position | 288,266 | 453,932 | 112,546 | 144,454 | 383,928 |
| End Cash Position | 180,070 | 288,266 | 453,932 | 112,546 | 144,454 |
| Net Cash Flow | $-108,196 | $-165,666 | $341,386 | $-31,908 | $-239,474 |
| Free Cash Flow | |||||
| Operating Cash Flow | 1,181,805 | 929,001 | 906,510 | 542,984 | 755,546 |
| Capital Expenditure | -124,676 | -120,922 | -133,631 | -148,838 | -119,549 |
| Free Cash Flow | 1,057,129 | 808,079 | 772,879 | 394,146 | 635,997 |